SmartPeptide
Start Free
Fat LossInvestigational — Phase 3Limited human evidence

Survodutide

Boehringer Ingelheim / Zealand Pharma dual GLP-1 / glucagon receptor agonist (BI 456906). Strong Phase 2 obesity + MASH (liver) data. Phase 3 SYNCHRONIZE program ongoing across weight management, T2D, and liver disease indications.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Phase 2 obesity (n≈387, 46 weeks): ~18.7% mean body weight reduction at 4.8 mg weekly vs. ~2.0% placebo. Phase 2 MASH trial showed significant resolution of MASH without worsening fibrosis. Phase 3 SYNCHRONIZE program ongoing.

What's still experimental

Pre-approval — all use is investigational. Direct head-to-head vs. retatrutide and tirzepatide not yet available. Long-term cardiovascular and hepatic safety under evaluation.

Anecdotal / community reports

Limited grey-market presence so far. Most public discussion focuses on the dual-agonist mechanism vs. triple-agonist (Retatrutide) tradeoffs.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “Survodutide”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

Source: Published clinical trial

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

Phase 2 trialLe Roux et al., Lancet 2024 (Phase 2 obesity)
Indication studied: Weight management (Phase 2 — not FDA-approved)
Citation: Le Roux CW et al., Lancet 2024
Phase 2 low
600µg
once weekly · subcutaneous

Lowest tested arm

Open calculator
Phase 2 mid
2.4mg(2,400 µg)
once weekly · subcutaneous

Mid-range arm

Open calculator
Phase 2 high
4.8mg(4,800 µg)
once weekly · subcutaneous

Highest tested arm — ~18.7% body weight reduction at 46 weeks

Open calculator

Notes from the source: Phase 3 SYNCHRONIZE program ongoing.

Important framing: The numbers above are what published trials tested or what FDA-approved labels specify. They are NOT a SmartPeptide recommendation for you. Trial doses come paired with screening, monitoring, and clinician oversight. Always consult a licensed clinician before any peptide use.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
No FDA enforcement actions (recalls, market withdrawals, safety alerts) on record for “Survodutide”. This is the expected baseline for most peptides — the absence of recalls does NOT imply general safety, only that no formal FDA enforcement has been initiated against approved formulations.

Mechanism & targets

ChEMBL · UniProt · Open Targets

Molecule (ChEMBL)

View on ChEMBL
Known mechanisms of action
  • CHEMBL1784
    agonistGlucagon-like peptide 1 receptor agonist
  • CHEMBL1985
    agonistGlucagon receptor agonist

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
82
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
4
26 total registered

Clinical trials (ClinicalTrials.gov)

All trials for "survodutide"

Europe PMC — 119 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
188
all years
Last 5 years
181
recent activity
Open access
166
freely readable
OA share
88%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Semantic Scholar API is currently rate-limited.

Human-study summaries for “survodutide OR BI 456906” are available on Semantic Scholar but the shared free-tier API quota is exhausted right now. Try refreshing in a few minutes, or check the PubMed and Europe PMC panels above for the same literature.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
222,951
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • National Natural Science Foundation of China31,735 works
  • National Key Research and Development Program of China4,630 works
  • Fundamental Research Funds for the Central Universities3,137 works
  • China Postdoctoral Science Foundation2,009 works
  • National Science Foundation1,395 works
  • Natural Science Foundation of Shandong Province1,269 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC
No preprints indexed yet for “survodutide OR BI 456906”.

Known risks

GI side effects, theoretical concerns about glucagon-receptor activation impact on glucose homeostasis and lipid metabolism. Long-term safety under evaluation. Hepatic effects of the glucagon component being closely monitored.

Reported side effects

Nausea, vomiting, diarrhea, decreased appetite, fatigue. GI dose-titration required.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
Reports filed
2
FAERS, all years
Serious reports
2
100% of reports
Top reporting countries
  • NZ1
  • US1

Most-reported reactions

  • Acute Kidney Injury
    2
  • Acute Myocardial Infarction
    1
  • Atrial Fibrillation
    1
  • Upper Gastrointestinal Haemorrhage
    1
  • Vomiting
    1

Counts from FDA Adverse Event Reporting System (FAERS). Voluntary reports — they show what was reported, not whether the drug caused the event. Many reports lack confirmation. FAERS docs

What requires medical supervision

Clinical-trial only. Patients should use FDA-approved options under prescriber care while awaiting approval.

Questions for your clinician

  • Is the glucagon receptor activation relevant to my metabolic profile?
  • Would a Phase 3 Survodutide trial be appropriate for me?
  • How does this differ mechanistically from Retatrutide?

Editorially curated references

Discussions about Survodutide

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all Survodutide discussions Native, moderated, no buying or selling